Abstract
Introduction: Lichen amyloidosus (LA) is the major variant of the primarycutaneous amyloidoses which present with severe and therapy resistant itching. Varioustherapeutic modalities such as antihistamines, intralesional injection or topical applicationof corticosteroids, etretinate, UVB irradiation and dermoabrasion have been employed withvariable success. Some authors have observed encouraging beneficial clinical effects by usingtopical dimethyl sulphoxide (DMSO). Objectives: The objective of the study was to: evaluatethe efficacy of topical Dimethyl sulfoxide (D.M.S.O) 70% in Lichen Amyloidosis. Study Design:Case series. Settings: This study was conducted at dermatology department, Abbasi ShaheedHospital in outpatient department (OPD). Duration of Study: The data collection was done in06 months after approval of synopsis. From: 2nd June 2013 to 2nd December 2013. Results: Inthis study, out of 71 cases, 42.25%(n=30) were between 16-40 years while 57.75%(n=41) werebetween 41-80 years of age, mean+sd was calculated as 41.79+10.87 years, 26.76%(n=19)were male and 73.24%(n=52) were females, 36.62%(n=26) had <6 months and 63.38%(n=45)had ≥6 months of duration, frequency of efficacy of topical dimethyl sulfoxide (D.M.S.O) in lichenamyloidosis reveals 66.20%(n=47) while 33.80%(n=24) did not show efficacy. Conclusion: Weconcluded that the efficacy of topical Dimethyl sulfoxide (D.M.S.O) 70% in Lichen Amyloidosisis higher and in accordancde with other studies. It may be utilized in future for such cases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.